chloroquine and derivatives - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.69 [0.28, 1.68]< 10%1 study (1/-)79.1 %NAnot evaluable crucial-
deaths 1.10 [0.58, 2.08]< 10%2 studies (2/-)38.5 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.21 [0.69, 2.12]< 10%1 study (1/-)25.2 %NAnot evaluable important-
clinical improvement (14-day) 0.83 [0.47, 1.44]> 10%1 study (1/-)25.1 %NAnot evaluable important-
clinical improvement (time to event analysis only) 0.85 [0.62, 1.16]> 10%1 study (1/-)14.7 %NAnot evaluable important-
hospital discharge 0.88 [0.64, 1.21]> 10%1 study (1/-)21.0 %NAnot evaluable important-
ICU admission 1.42 [0.79, 2.55]< 10%1 study (1/-)12.0 %NAnot evaluable non important-

safety endpoints 00

adverse events 0.88 [0.29, 2.65]< 10%1 study (1/-)59.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.